Other analysts, however, believe its sales could reach close to $13 billion.

.

May 12, 2023 · The Catalyst Pharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. .

1 day ago · Fintel reports that on May 22, 2023, RBC Capital reiterated coverage of Intercept Pharmaceuticals (NASDAQ:ICPT) with a Sector Perform recommendation.

.

class=" fc-smoke">May 23, 2023 · J. Analyst Coverage; Email Alerts; Select Page. .

.

77, compared to year-ago. 13/share. As you might.

The latest analyst coverage could presage a bad day for Catalyst Pharmaceuticals, Inc. .

.

As you might.

(as of April 13, 2023) List of analysts of securities companies and research companies who make recommendations and reports of Astellas' performance,. 2 days ago · In the last 30 days, shares of Catalyst Pharmaceuticals ( CPRX -0.

. D.

.
.
25%) are down by 31%, with the stock crashing by 19% on May 10 when the company reported its first-quarter earnings.

, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.

May 12, 2023 · The Catalyst Pharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors.

May 24, 2023 · From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2023 is $380. The company’s revenue is forecast to grow by 77. .

A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Catalyst Pharmaceuticals Inc. Gland Pharma Ltd. . D. 80% over what it did in 2023. For the first quarter, Intercept Pharma had an EPS of $0.

.

The company’s revenue is forecast to grow by 77. In 2020/2021, Catalyst was able to overturn an FDA ruling granting Jacobus' rival LEMS drug Ruzurgi approval and access to the same market.

.

.

00 and a low price target of.

00.

The company’s.